AbbVie, Galapagos expand RA deal for Crohn's study
This article was originally published in Scrip
Executive Summary
AbbVie and Belgium-based biotechnology firm Galapagos are extending their previous oral, next-generation Janus kinase (JAK) 1 inhibitor development deal to include Crohn's disease.